Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 10;14(6):1420.
doi: 10.3390/cancers14061420.

PARP Inhibitors Resistance: Mechanisms and Perspectives

Elena Giudice  1 , Marica Gentile  2 , Vanda Salutari  3 , Caterina Ricci  3 , Lucia Musacchio  3 , Maria Vittoria Carbone  3 , Viola Ghizzoni  1 , Floriana Camarda  4 , Francesca Tronconi  5 , Camilla Nero  3 , Francesca Ciccarone  3 , Giovanni Scambia  1   3 , Domenica Lorusso  1   3
Affiliations
Review

PARP Inhibitors Resistance: Mechanisms and Perspectives

Elena Giudice et al. Cancers (Basel). .

Abstract

PolyADP-ribose polymerase (PARP) inhibitors (PARPis) represent the first clinically approved drugs able to provoke "synthetic lethality" in patients with homologous recombination-deficient (HRD) tumors. Four PARPis have just received approval for the treatment of several types of cancer. Besides, another three additional PARPis underlying the same mechanism of action are currently under investigation. Despite the success of these targeted agents, the increasing use of PARPis in clinical practice for the treatment of different tumors raised the issue of PARPis resistance, and the consequent disease relapse and dismal prognosis for patients. Several mechanisms of resistance have been investigated, and ongoing studies are currently focusing on strategies to address this challenge and overcome PARPis resistance. This review aims to analyze the mechanisms underlying PARPis resistance known today and discuss potential therapeutic strategies to overcome these processes of resistance in the future.

Keywords: BRCA; DNA damage repair; PARP inhibitor resistance; homologous recombination; ovarian cancer; polyADP-ribose polymerase (PARP) inhibitor; replication fork.

PubMed Disclaimer

Conflict of interest statement

V.S. reports grants from Clovis Oncology, grants from TESARO, grants from GSK, grants from Astra Zeneca, grants from MSD, grants from PHARMAMAR, grants from EISAI, grants from ROCHE, outside the submitted work; G.S. reports personal fees from ROCHE, personal fees from Clovis Oncology, personal fees from Astra Zeneca, personal fees from PharmaMar, personal fees from Tesaro, outside the submitted work; D.L. reports grants from ROCHE, grants and personal fees from GSK, grants and personal fees from Clovis Oncology, grants and personal fees from MSD, grants from Incyte, grants and personal fees from PHARMAMAR, grants from IMMUNOGEN, grants and personal fees from GENMAB, personal fees from AMGEN, grants and personal fees from Astra Zeneca, outside the submitted work; E.G., M.G., C.R., L.M., M.V.C., V.G., F.C (Floriana Camarda). F.T., C.N. and F.C. (Francesca Ciccarone) have nothing to disclose. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Mechanism of action of polyADP-ribose polymerase (PARP) inhibitors. Step 1: DNA damage caused by PARP inhibitors, with consequent creation of single strand DNA break (SSB); Step 2: detection of SSB by PARP1; Step 3: production of DNA protein crosslinks; Step 4: collapse of replication forks and double strand DNA breaks (DSBs) accumulation. While in homologous recombination (HR)-proficient cells these errors are restored by HR system, in HR-deficient tumor cells this process finally results in cell death.
Figure 2
Figure 2
Mechanism of resistance to polyADP-ribose polymerase (PARP) inhibitors. Several resistance mechanisms have been identified: reversion mutation, DNA polymerase θ (POLQ), loss of shieldin complex, stabilization of replication fork, increased drug efflux, overexpression of cyclin-dependent kinase 12 (CDK12) and WEE1.
See this image and copyright information in PMC

References

    1. Ait Saada A., Lambert S.A.E., Carr A.M. Preserving Replication Fork Integrity and Competence via the Homologous Recombination Pathway. DNA Repair. 2018;71:135–147. doi: 10.1016/j.dnarep.2018.08.017. - DOI - PMC - PubMed
    1. Tarsounas M., Sung P. The Antitumorigenic Roles of BRCA1–BARD1 in DNA Repair and Replication. Nat. Rev. Mol. Cell Biol. 2020;21:284–299. doi: 10.1038/s41580-020-0218-z. - DOI - PMC - PubMed
    1. Lord C.J., Ashworth A. BRCAness Revisited. Nat. Rev. Cancer. 2016;16:110–120. doi: 10.1038/nrc.2015.21. - DOI - PubMed
    1. Robson M., Im S.-A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N., Armstrong A., et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 2017;377:523–533. doi: 10.1056/NEJMoa1706450. - DOI - PubMed
    1. Golan T., Hammel P., Reni M., van Cutsem E., Macarulla T., Hall M.J., Park J.-O., Hochhauser D., Arnold D., Oh D.-Y., et al. Maintenance Olaparib for Germline BRCA—Mutated Metastatic Pancreatic Cancer. N. Engl. J. Med. 2019;381:317–327. doi: 10.1056/NEJMoa1903387. - DOI - PMC - PubMed

LinkOut - more resources